|
|
Article: Antares Pharma Announces Milestone Payment From Its Licensing Agreement With Lilly.
- Article from:
- PR Newswire
- Article date:
- December 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antares Pharma, Inc. (BULLETIN BOARD: ANTR) today announced that it has received a milestone payment from Eli Lilly and Company , the licensee of Antares Pharma's needle-free injection technology in the fields of diabetes and obesity. This milestone payment followed the successful outcome of a meeting held with representatives of the Food and Drug Administration on November 6, 2003, at which the companies were able to clarify the regulatory expectations for the ongoing development program.
Dr. Roger G. Harrison, Chief Executive Officer and President of Antares Pharma, said, "We are pleased with the outcome of the meeting with the FDA, which was attended by ...
Related newspaper, magazine, and journal articles:
|
|
Article: Antares Pharma, Inc. Reports First Quarter 2004 ...
PR Newswire;
May 14, 2004 ;
700+ words
... ... growth hormone -- Received milestone payment from license agreement with ... 11,736 28,627 144% Antares Pharma, Inc. (BULLETIN BOARD ... February and March 2004. About Antares Pharma Antares Pharma develops specialty pharmaceutical ...
|
|